Evidence map›Paper›PMID 31756174›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Upregulation of Protease-Activated Receptor 2 Promotes Proliferation and Migration of Human Vascular Smooth Muscle Cells (VSMCs).

Mei Wei, Yongsheng Liu, Mingqi Zheng, Le Wang, Fangfang Ma, Yanchao Qi, Gang Liu

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Frontiers in genetics · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mei WeiHeart Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Yongsheng LiuDepartment of General Family Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Mingqi ZhengHeart Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Le WangHeart Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Fangfang MaHeart Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Yanchao QiHeart Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Gang LiuHeart Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Hebei Medical University · CNFirst Affiliated Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Protease-Activated Receptor 2 (PAR2), a G-protein-coupled receptor, has been proved to be enhanced in human coronary atherosclerosis lesions. We aimed to investigate whether PAR2 actively participates in the atherosclerosis process. MATERIAL AND METHODS PAR2 expression was assessed in blood samples by RT-qPCR from healthy controls and patients with atherosclerosis. Human vascular smooth muscle cells (VSMCs) were treated with oxidative low-density lipoprotein (ox-LDL). After PAR2 overexpression by transfection, cell proliferation was determined by CCK-8, and cell migration was evaluated by Transwell assay. The protein expressions associated with cell growth and migration were measured by Western blot. The distribution of alpha-SMA in VSMCs was evaluated by immunofluorescence. RESULTS Expression of PAR2 was higher in patients with atherosclerosis compared with normal controls. PAR2 mRNA and protein expression was increased in ox-LDL-treated VSMCs compared with control cells. Induced overexpression of PAR2 in VSMCs led to a reduction in alpha-SMA expression compared to controls. In addition, PAR2 overexpression caused increased migration compared to normal controls, and upregulated MMP9 and MMP14 expression. PAR-2 overexpression promoted cell proliferation compared to control cells, and increased expression levels of CDK2, and CyclinE1, but reduced levels of p27. We preliminary explored the potential mechanism of PAR2, and results showed that overexpression of PAR2 increased expression levels of VEGFA and Angiopoietin 2 compared to controls. Moreover, overexpression of PAR2 enhanced production of tissue factor and IL-8 compared to normal controls. CONCLUSIONS PAR2 promotes cell proliferation and disrupts the quiescent condition of VSMCs, which may be a potential therapeutic target for atherosclerosis.

Indexed as

AdultAtherosclerosisCell LineCell MovementCell ProliferationChinaCyclin-Dependent Kinase 2FemaleHumansLipoproteins, LDLMaleMatrix Metalloproteinase 9Middle AgedMuscle, Smooth, VascularMyocytes, Smooth MuscleReceptor, PAR-2CDK2 protein, humanCyclin-Dependent Kinase 2Lipoproteins, LDLMatrix Metalloproteinase 9oxidized low density lipoproteinReceptor, PAR-2Receptors, G-Protein-CoupledRNA, Messenger

Identifiers

PMID31756174
PMCPMC6883764
OpenAlexW2990881576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.